Table 2 Analysis in patients matched on IPI risk score.

From: A non-randomized risk-adjusted comparison of lenalidomide + R-CHOP versus R-CHOP for MYC-rearranged DLBCL patients

 

R-CHOP (N = 46)

R2CHOP (N = 46)

Total (N = 92)

p-value

Age at incidence (years)

   

0.110a

 Median

70

65

68

 

 IQR

57–76

58–72

57–75

 

 Range

29–88

28–82

28–88

 

Sex

   

0.829b

 Male

28 (60.9%)

30 (65.2%)

58 (63.0%)

 

 Female

18 (39.1%)

16 (34.8%)

34 (37.0%)

 

Ann Arbor stage

   

0.258c

 2

9 (19.6%)

10 (21.7%)

19 (20.7%)

 

 3

11 (23.9%)

5 (10.9%)

16 (17.4%)

 

 4

26 (56.5%)

31 (67.4%)

57 (62.0%)

 

WHO performance score

   

0.167c

 0

19 (43.2%)

30 (65.2%)

49 (54.4%)

 

 1

14 (31.8%)

11 (23.9%)

25 (27.8%)

 

 2

8 (18.2%)

4 (8.7%)

12 (13.3%)

 

 3

3 (6.8%)

1 (2.2%)

4 (4.4%)

 

 (Missing)

2

0

2

 

WHO PS (grouped)

   

0.083c

 0

19 (43.2%)

30 (65.2%)

49 (54.4%)

 

 1

14 (31.8%)

11 (23.9%)

25 (27.8%)

 

 2 or 3

11 (25.0%)

5 (10.9%)

16 (17.8%)

 

 (Missing)

2

0

2

 

LDH

   

1.000b

 Within normal range

13 (28.3%)

13 (28.3%)

26 (28.3%)

 

 Elevated

33 (71.7%)

33 (71.7%)

66 (71.7%)

 

Extra-nodal localizations

   

0.536c

 None

11 (23.9%)

13 (28.3%)

24 (26.1%)

 

 1

17 (37.0%)

12 (26.1%)

29 (31.5%)

 

 2 or more

18 (39.1%)

21 (45.7%)

39 (42.4%)

 

IPI risk group

   

0.836c

 Low

9 (19.6%)

9 (19.6%)

18 (19.6%)

 

 Low-intermediate

8 (17.4%)

11 (23.9%)

19 (20.7%)

 

 High-intermediate

13 (28.3%)

10 (21.7%)

23 (25.0%)

 

 High

16 (34.8%)

16 (34.8%)

32 (34.8%)

 

IPI risk (3 Groups)

   

1.000c

 Low

9 (19.6%)

9 (19.6%)

18 (19.6%)

 

 Intermediate

21 (45.7%)

21 (45.7%)

42 (45.7%)

 

 High

16 (34.8%)

16 (34.8%)

32 (34.8%)

 

Rearrangement

   

0.113b

 Single hit

14 (30.4%)

15 (32.6%)

29 (31.5%)

 

 Double/triple hit

22 (47.8%)

28 (60.9%)

50 (54.3%)

 

 Missing BCL2/BCL6

10 (21.7%)

3 (6.5%)

13 (14.1%)

 

Days before start treatment

   

0.072a

 Median

15.5

21.5

19.0

 

 IQR

12.0–25.2

15.2–27.8

13.0–27.0

 

 Range

5.0–84.0

2.0–69.0

2.0–84.0

 

Response

   

0.351c

 Complete remission

29 (67.4%)

38 (82.6%)

67 (75.3%)

 

 Partial remission

10 (23.3%)

6 (13.0%)

16 (18.0%)

 

 Stable disease

1 (2.3%)

0 (0.0%)

1 (1.1%)

 

 Progressive disease

3 (7.0%)

2 (4.3%)

5 (5.6%)

 

 (Missing)

3

0

3

 
  1. aKruskal–Wallis rank sum test.
  2. bFisher’s Exact Test for Count Data.
  3. cTrend test for ordinal variables.
Back to article page